Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Miniature In-line Respirator

First-In-Human Trial of Miniature In-Line, Pressure-Cycled, Emergency Respirator Device in Human Organ Donors

This first-in-human pilot study will test an investigational miniature breathing device called the Hope inVent. The device is a small, single-use, in-line respirator that connects to a breathing tube and uses compressed oxygen to help move air in and out of the lungs. It has no moving parts and is designed to provide short-term breathing support in situations where standard ventilators may not be available, such as emergencies, disasters, battlefield settings, transport, or ventilator shortages.

The study will enroll up to 5 brain-dead organ donors who are already receiving mechanical ventilation at the Gift of Life Donor Care Center at the Hospital of the University of Pennsylvania. Donors will only be included after authorization for organ donation and research has been obtained through standard procedures. Donors who may donate lungs or who have significant lung disease will not be included.

During the study, investigators will briefly replace the standard ventilator with the Hope inVent device for up to 15 minutes. The standard ventilator will remain immediately available, and the donor will be continuously monitored by the clinical and research teams. Investigators will measure whether the device can maintain acceptable breathing measures, including oxygen level and carbon dioxide level. They will also record breathing pressures and tidal volume, which is the amount of air delivered with each breath. If the device does not perform as expected or if any safety concern occurs, the donor will be returned immediately to the standard ventilator.

There is no direct benefit to the organ donor. Information from this study may help determine whether this type of simple, low-cost breathing device could be useful for future patients who need emergency or short-term ventilator support when standard ventilators are not available.

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Detaljert beskrivelse

Study Description:

Proof of Concept pilot study to support use of a miniature in-line patient respirator for patient ventilation needs.

Objectives:

Primary Objective:

To assess the effectiveness of the miniature respirator to ventilate intubated braindead research donors while maintaining respiratory measures within acceptable range.

Secondary Objective

The miniature respirator performs as designed and tested in a lung simulator.

Endpoints:

Primary Endpoint:

A binary variable equal to 1 ("success") if both of the following criteria are met (during the placement of the test device):

  1. the respirator maintains the end tidal CO(2) between 35- and 45-mm Hg;

    and

  2. the O(2) saturation measured by pulse oximetry is > 94%.

Otherwise, the primary endpoint is equal to 0 ("failure").

Secondary Endpoints:

Binary variables equal to 1 ("success") if tidal volume and airway pressure settings (PEEP and maximum peak airway pressure) are within 30% of predicted values. Otherwise, the secondary endpoints are equal to 0 ("failure").

Studietype

Intervensjonell

Registrering (Antatt)

5

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Hospital of the University of Pennsylvania
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 år til 100 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

  • INCLUSION CRITERIA

    1. Diagnosis of brain death
    2. Provision of signed and dated informed consent form for organ donation and research by donor family or surrogate decisionmaker.
    3. Male or female, with no age restriction (see size exclusion).
    4. Decedent transferred to the Gift of Life at Penn Medicine Donor Care Center (study site) for routine organ donor management and organ recovery procedures.

EXCLUSION CRITERIA

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Brain-dead research donor will be excluded if their baseline CO(2) or pulse oximetry is out of the accepted range for the study (defined as end tidal CO(2) between 35- and 45-mm Hg and the O(2) saturation measured by pulse oximetry > 94%) while on optimized ventilation.

  2. Brain-dead research donors with severe respiratory disease. This may include:

    • Bullous lung disease - noted on pre-op imaging or by history.
    • h/o pneumothoraces
    • h/o severe asthma, COPD, or other significant lung disease
  3. Brain-dead research donors with morbid obesity (BMI >=40).

  4. Brain-dead research donor body weight of < 25kg.

  5. Potential Brain-dead lung transplant donors (as determined by Gift of Life Donor Program staff according to at the time of study site (Donor Care Center) admission)

  6. Intraoperative arterial blood gas values outside the range of normal for pH, PaO2, PaCO2, HCO3, O2Sat as measured in pre-device ABG (while on optimized ventilation).

Acceptable range for Arterial Blood Gas (ABG values)

Parameter - pH / Range - 7.35-7.45

Parameter - PaO2 / Range - >=75 mm Hg

Parameter - PaCO2 / Range - 35-45 mm Hg

Parameter - HCO3 / Range - 22-26 mEq/L

Parameter - SpO2 / Range - 94-100

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Enhetens gjennomførbarhet
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Hope inVent Miniature In-line Respirator

All enrolled brain-dead organ donors who meet eligibility criteria will receive the investigational Green Hope inVent miniature in-line, pressure-cycled respirator for up to 15 minutes. Respiratory and physiologic measures will be collected before device placement while the donor is on the standard mechanical ventilator and during use of the Hope inVent device. Each donor serves as their own control; there is no separate comparator arm. The standard ventilator will remain available, and donors will be returned to standard ventilation after testing or earlier if safety or performance criteria require.

The Hope inVent is an investigational, single-use, miniature in-line respirator designed to provide short-term ventilatory support for intubated individuals. The device is a 3D-printed, pressure-cycled, gas-powered respirator with no moving parts. It connects to the endotracheal tube breathing circuit and uses compressed oxygen as its power source. In this study, only the Green Hope inVent model will be used. The device cycles between fixed pressure settings: peak inspiratory pressure of 18 cm H2O and positive end-expiratory pressure of 6 cm H2O. Enrolled brain-dead research donors will be placed on the device once for up to 15 minutes, with continuous respiratory and physiologic monitoring. The donor will then be returned to the standard mechanical ventilator.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of donors with successful ventilation and oxygenation during Hope inVent testing.
Tidsramme: During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

Success is defined as maintaining both end-tidal carbon dioxide between 35 and 45 mm Hg and oxygen saturation by pulse oximetry greater than 94% during placement of the Hope inVent device. If either criterion is not met, or if device use is stopped early because of inadequate ventilation or oxygenation, the outcome is classified as failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of donors with tidal volume within 30% of predicted value
Tidsramme: During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

Tidal volume will be measured using an in-line respiratory monitor while the donor is ventilated with the Hope inVent device. Each donor will be classified as a success if tidal volume is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes.
Proportion of donors with positive end-expiratory pressure within 30% of predicted value
Tidsramme: During device use, from connection of the Hope inVent device to removal, up to 15 minutes

Positive end-expiratory pressure will be measured using an in-line respiratory monitor during Hope inVent ventilation. Each donor will be classified as a success if positive end-expiratory pressure is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes
Proportion of donors with maximum peak airway pressure within 30% of predicted value
Tidsramme: During device use, from connection of the Hope inVent device to removal, up to 15 minutes

Maximum peak airway pressure will be measured using an in-line respiratory monitor during Hope inVent ventilation. Each donor will be classified as a success if maximum peak airway pressure is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Andrew J Mannes, M.D., National Institutes of Health Clinical Center (CC)

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

9. november 2026

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

14. august 2026

Først innsendt som oppfylte QC-kriteriene

14. august 2026

Først lagt ut (Faktiske)

17. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

12. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified or anonymized individual donor-level data may be shared with collaborating investigators or institutions at NIH, the University of Pennsylvania, or outside institutions, and/or submitted to NIH-designated databases, consistent with donor authorization, applicable IRB approvals, NIH policies, and federal regulations. Shared data will not include direct identifiers. If coded data are shared, the code key will not be provided to collaborators. No biospecimens will be stored or shared for future use.

IPD-delingstidsramme

De-identified or anonymized individual participant data and supporting information may become available after publication of the primary study results or posting of summary results on ClinicalTrials.gov, subject to applicable consent/authorization, IRB approvals, data-use agreements, and NIH/federal requirements.

Tilgangskriterier for IPD-deling

De-identified or anonymized donor-level data may be shared with qualified investigators at NIH, the University of Pennsylvania, or other institutions upon written request to the Principal Investigator. Requests must describe the proposed scientific use, such as analyses of device performance, respiratory/physiologic outcomes, safety, or related protocol objectives. Requests will be reviewed by the study team/sponsor and shared only as permitted by donor authorization, IRB approvals, institutional policies, data-use or collaboration agreements, and NIH/federal requirements. Data may be shared with investigators/institutions with a Federalwide Assurance or operating under the Declaration of Helsinki; other sharing will require prospective IRB approval. Data may be transferred securely or submitted to an NIH-designated database. Direct identifiers and code keys will not be shared.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere